| Previous Close | 23.45 |
| Open | 23.29 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 22.01 - 23.85 |
| 52 Week Range | 22.01 - 1,200.00 |
| Volume | 156,045 |
| Avg. Volume | 192,722 |
| Market Cap | 723.601M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -21.92 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.67 |
Stoke Therapeutics, Inc. , a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its initial public offering of 9,074,776 shares of its common stock at a price to the public of $18.00 per share, which includes 1,183,666 shares sold upon full exercise of the underwriters’ option ...
Stoke Therapeutics Inc. shares rocketed 46% in their trading debut Wednesday, after the company's initial public offering priced above its $14 to $16 price range. The company sold 7.9 million shares priced at $18 each to raise $142 million. Proceeds of the deal will be used to advance clinical trials of its lead product candidate STK-001, a treatment for the severe form of epilepsy Dravet syndrome. JPMorgan, Cowen, Credit Suisse and Canaccord were underwriters on the deal.
Stoke Therapeutics, Inc. (NASDAQ: STOK ) opened Wednesday morning at $27.21 per share. The company priced 7 million shares of common stock at $18 per share. JPMorgan, Cowen, Credit Suisse and Cannacord ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals ...
Stoke Therapeutics, Inc., a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of its initial public offering of 7,891,110 shares of its common stock at a price to the public of $18.00 per share. All of the shares are being offered by Stoke. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke, are expected to be approximately $142.0 million.
Stoke Therapeutics, Inc. this week proposes to offer 6.7 million shares at an estimated price range of $14-$16, according to an amended S-1 filing from June 12. The company seeks to list its shares on the Nasdaq under the ticker symbol STOK. As Stoke qualifies as an "emerging growth company" and a "smaller reporting company" under the federal securities laws, it has the leeway to comply with certain reduced disclosure norms.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...